(3R)-1-benzyl-3-[[3-(trifluoromethyl)phenyl]methyl]piperazine | 1084795-94-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (3R)-1-benzyl-3-[[3-(trifluoromethyl)phenyl]methyl]piperazine
• CAS: 1084795-94-7
• 化学式: C₁₉H₂₁F₃N₂
• 分子量: 334.384
• InChiKey: RKNQEBJSYFWXTM-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (3R)-1-benzyl-3-[[3-(trifluoromethyl)phenyl]methyl]piperazine 在 吡啶 、 四磷十氧化物 、 palladium 10% on activated carbon 、 氢气 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 生成 (R)-9-(Trifluoromethyl)-3,4,11,11a-tetrahydro-1H-pyrazino[1,2-b]isoquinolin-6(2H)-one
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061
• 作为产物：
  描述：

  Boc-D-Phe(3-CF3)-N(Bn)Gly-OEt 在 盐酸 、 lithium aluminium tetrahydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 1,2-二氯乙烷 为溶剂， 生成 (3R)-1-benzyl-3-[[3-(trifluoromethyl)phenyl]methyl]piperazine
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061

文献信息

• Substituted imidazole compound and use thereof
  申请人：Kuroita Takanobu

  公开号：US20090227560A1

  公开（公告）日：2009-09-10

  The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension, and the like.

  本发明涉及一种由以下式表示的化合物：其中每个符号如描述中所定义，或其盐或前药。本发明的化合物具有优越的肾素抑制活性，因此可用作预防或治疗高血压、由高血压引起的各种器官损伤等的药物。
• [EN] SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ D'IMIDAZOLE SUBSTITUÉ ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2008139941A1

  公开（公告）日：2008-11-20

  [EN] The present invention relates to a compound represented by the formula: wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension, and the like.
  [FR] La présente invention concerne un composé représenté par la formule : dans laquelle chaque symbole est tel que défini dans la description, ou l'un de ses sels ou précurseurs. Le composé de la présente invention possède une activité supérieure d'inhibition de la rénine et est ainsi utile en tant qu'agent destiné à la prophylaxie ou au traitement de l'hypertension, de diverses lésions d'organes attribuables à l'hypertension et analogues.
• Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists
  作者：Guohua Zhao、Chet Kwon、Sharon N. Bisaha、Philip D. Stein、Karen A. Rossi、Xueying Cao、Thao Ung、Ginger Wu、Chen-Pin Hung、Sarah E. Malmstrom、Ge Zhang、Qinling Qu、Jinping Gan、William J. Keim、Mary Jane Cullen、Kenneth W. Rohrbach、James Devenny、Mary Ann Pelleymounter、Keith J. Miller、Jeffrey A. Robl

  DOI：10.1016/j.bmcl.2013.04.061

  日期：2013.7

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.